Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Raised by Valley National Advisers Inc.

Valley National Advisers Inc. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,453 shares of the biopharmaceutical company’s stock after purchasing an additional 59 shares during the period. Valley National Advisers Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,398,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of REGN. West Paces Advisors Inc. lifted its stake in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares in the last quarter. Fortitude Family Office LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. MCF Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Criterion Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $37,000. Finally, Bruce G. Allen Investments LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $40,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN traded down $20.57 during midday trading on Wednesday, reaching $1,024.09. The company’s stock had a trading volume of 378,341 shares, compared to its average volume of 477,749. The stock has a market cap of $112.84 billion, a P/E ratio of 30.25, a PEG ratio of 2.17 and a beta of 0.13. The company has a fifty day simple moving average of $990.15 and a 200 day simple moving average of $954.11. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $688.52 and a twelve month high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on REGN shares. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. JPMorgan Chase & Co. raised their price target on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Monday, June 17th. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $925.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Finally, Argus raised their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $1,027.55.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Bonnie L. Bassler sold 756 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,467,684. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 63,208 shares of company stock valued at $62,514,142. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.